Back

Severe acute myositis and myocarditis upon initiation of six-weekly Pembrolizumab post-COVID-19 mRNA vaccination

Watson, R. A.; Ye, W.; Taylor, C. A.; Cooper, R. A.; Tong, O.; James, T.; Shine, B.; Hofer, M.; Jenkins, D.; Pell, R.; Ieremia, E.; Jones, S.; Maldonado-Perez, D.; Roberts, I.; Coupe, N.; Middleton, M. R.; Payne, M. J.; Fairfax, B. P.

2023-11-27 oncology
10.1101/2023.11.24.23296021 medRxiv
Show abstract

We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within one month of receiving the initial cycle of the anti-PD-1 drug Pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognising viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.